Nefopam


Concise Prescribing Info
Indications/Uses
Moderate acute and chronic pain.
Dosage/Direction for Use
Adult: PO Initial: 60 mg tid. Usual dose: 30-90 mg tid, adjusted according to patient's response.
Administration
May be taken with or without food. May be taken w/ meals if GI discomfort occurs.
Contraindications
History of convulsive disorders. Concomitant use w/ MAOI(s).
Special Precautions
Patient w/ angle closure glaucoma, urinary retention, history of ischaemic heart disease. Hepatic and renal impairment. Elderly, childn. Pregnancy and lactation. Patient Counselling This drug may cause drowsiness, if affected, do not drive or operate machinery.
Adverse Reactions
Significant: Sympathomimetic effect (e.g. tachycardia, aggravation or precipitation of angina). Rarely, pink discolouration of urine. Nervous: Insomnia, drowsiness, dizziness, paraesthesia, tremor, lightheadedness, nervousness, confusion, hallucinations, headache, syncope, euphoria, convulsions. CV: Hypotension, palpitations, tachycardia. GI: Nausea, vomiting, dry mouth, abdominal pain, diarrhoea. Genitourinary: Urinary retention. Ophthalmologic: Blurred vision. Dermatologic: Sweating, angioedema. Immunologic: Hypersensitivity reactions (e.g. erythema multiforme, anaphylaxis).
Drug Interactions
Increased risk of convulsion w/ TCA. Additive adverse effect w/ other antimuscarinic or sympathomimetic agents.
ATC Classification
N02BG06 - nefopam ; Belongs to the class of other analgesics and antipyretics.
Disclaimer: This information is independently developed by CIMS based on nefopam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in